Latest Amri Stories
ALBANY, N.Y., May 15, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that Michael M. Nolan, Vice President, Chief Financial Officer and Treasurer at AMRI, will present at the UBS Global Healthcare Conference on Wednesday, May 22, 2013 at 9:00 a.m. ET. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO) An audio webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at www.amriglobal.com....
Total First Quarter Revenue up 11% at $59.4 Million and Adjusted EPS increased to $0.23 ALBANY, N.Y., May 7, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today reported financial and operating results for the first quarter ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO) Financial highlights for the first quarter include: Adjusted diluted earnings per share of $0.23, an increase of $0.21 from the prior-year period Contract revenue of $46.5...
ALBANY, N.Y., April 24, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue first quarter financial results before the opening of the market on Tuesday, May 7, 2013. Following the release of its results, the company will host a conference call and simultaneous webcast at 10 a.m. ET. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) The conference call can be accessed by dialing 888-556-4997 (domestic calls) or 719-325-2452 (international calls) at...
New Agreement Extends Drug Discovery and Development Collaboration Between the Companies ALBANY, N.Y., April 23, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has entered into a new five-year service agreement with Ono Pharmaceutical Company, Ltd., (TSE: 4528), a pharmaceutical company headquartered in Osaka, Japan. Under the terms of the agreement, AMRI may provide a range of services from early drug discovery to cGMP manufacturing. (Logo:...
ALBANY, N.Y., April 23, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that AMRI Chairman, President and Chief Executive Officer Thomas E. D'Ambra, Ph.D. will present at the 12(th) Annual Needham Healthcare Conference on Tuesday, April 30, 2013 at 12:50 p.m. ET. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) A webcast of the corporate presentation will be available to investors and interested parties by accessing the company's website at...
Integrated Leadership of Singapore and India Strengthens SMARTSOURCING(TM) Platform ALBANY, N.Y., Feb. 25, 2013 /PRNewswire/ -- AMRI announced today that it has promoted Takeshi Yura, Ph.D., to Vice President of Discovery and Development Services, Asia. Dr. Yura will report directly to Thomas E. D'Ambra, Ph.D., Chairman, President and CEO. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO) Dr. Yura joined AMRI in January 2011 and most recently served as Senior...
ALBANY, N.Y. and REDWOOD CITY, Calif., Feb. 13, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) and Codexis (NASDAQ: CDXS) announced today that they have entered into a SMARTSOURCING(TM) partnership. The collaboration will provide opportunities to combine the two companies' capabilities and technologies for specific customer projects, yielding increased value to customers in the form of potentially lower costs, greater yields, cleaner processes and/or faster turnaround times. (Logo:...
ALBANY, N.Y., Feb. 12, 2013 /PRNewswire/ -- AMRI (Nasdaq: AMRI) today reported financial and operating results for the fourth quarter and full year ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO) Fourth Quarter: Adjusted earnings per share of $0.17, an increase of $0.36 from the prior-year period Contract revenue of $59.1 million, up 50% from the prior-year period with sequential revenue improvement in Discovery and Large Scale...
ALBANY, N.Y., Feb. 11, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has signed an exclusive license agreement with Chai Therapeutics, LLC for the development of ALB 109564(a), AMRI's novel tubulin inhibitor compound in late Phase I testing for the treatment of cancer. This agreement follows the exercise of an option to license the intellectual property, which was granted in March 2012 by AMRI to Bessor Pharma, LLC, a translational drug development company. Chai...
ALBANY, N.Y., Jan. 15, 2013 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced it will issue fourth quarter and full year financial results before the opening of the market on Tuesday, February 12, 2013. Following the release of its results, the company will host a conference call and simultaneous webcast at 10 a.m. ET. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) The conference call can be accessed by dialing 888-438-5535 (domestic calls) or 719-325-2455...
